We are live on
!
Find out more
FM
Frazier Management Portfolio holdings
AUM
$1.12M
1-Year Est. Return
151.58%
This Fund
S&P 500
This Quarter
Est. Return
+3.35%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$49.1M
(+3.9%)
Cap. Flow
+$130M
Cap. Flow
% of AUM
10.05%
Top 10 Holdings %
Top 10 Hldgs %
55.9%
Holding
47
New
6
Increased
12
Reduced
2
Closed
4
Avg Time Held
5.9
quarters
Top 10 Avg Time Held
4.4
quarters
Top 20 Avg Time Held
5.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Syndax Pharmaceuticals
SNDX
|
+$29.3M |
| 2 |
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
|
+$28.6M |
| 3 |
Silence Therapeutics
SLN
|
+$20.5M |
| 4 |
KalVista Pharmaceuticals
KALV
|
+$18.3M |
| 5 |
Merus
MRUS
|
+$15.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
+$55M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$20.4M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
+$2.65M |
| 4 |
Galera Therapeutics, Inc. Common Stock
GRTX
|
+$1.95M |
| 5 |
FRLN
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
|
+$1.88M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.85% |
| 2 | Miscellaneous | 1.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Arcutis Biotherapeutics
ARQT
$3.28B
| $175M | 13.47% |
8,434,232
| – | – |
2020 Q1
7 quarters
|
|
2
Phathom Pharmaceuticals
PHAT
$566M
| $115M | 8.82% |
5,827,415
| – | – |
2019 Q4
8 quarters
|
|
|
IMGO
3
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $70.4M | 5.42% |
2,971,274
| – | – |
2021 Q3
1 quarter
|
|
|
4
Syndax Pharmaceuticals
SNDX
$1.25B
| $60.7M | 4.67% |
2,772,062
+1,583,927
| +133% | +$29.3M |
2020 Q1
7 quarters
|
|
5
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $60M | 4.62% |
4,667,242
| – | – |
2018 Q3
13 quarters
|
|
6
Mirum Pharmaceuticals
MIRM
$5.17B
| $56.9M | 4.38% |
3,566,912
| – | – |
2019 Q3
9 quarters
|
|
7
Vaxcyte
PCVX
$10.4B
| $54.9M | 4.23% |
2,309,554
| – | – |
2020 Q2
6 quarters
|
|
8
Krystal Biotech
KRYS
$9.51B
| $53.9M | 4.15% |
771,250
| – | – |
2018 Q3
13 quarters
|
|
|
PRDS
9
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $40.2M | 3.1% |
+2,457,507
| New | +$28.6M |
2021 Q4
0 quarters
|
|
10
DELISTED
Crinetics Pharmaceuticals
CRNX
| $39.3M | 3.03% |
1,384,293
+532,987
| +63% | +$13.1M |
2021 Q3
1 quarter
|
|
|
KDNY
11
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $38.7M | 2.98% |
2,371,918
+700,000
| +42% | +$9.96M |
2021 Q2
2 quarters
|
|
12
Bicycle Therapeutics
BCYC
$254M
| $33.8M | 2.6% |
555,240
+112,360
| +25% | +$6.2M |
2021 Q3
1 quarter
|
|
|
13
Iovance Biotherapeutics
IOVA
$6.57B
| $33.4M | 2.57% |
1,747,622
-926,677
| -35% | -$20.4M |
2016 Q2
22 quarters
|
|
14
Tarsus Pharmaceuticals
TARS
$3.31B
| $31.9M | 2.45% |
1,417,157
| – | – |
2020 Q4
4 quarters
|
|
15
Passage Bio
PASG
$11.7M
| $31.8M | 2.45% |
250,461
| – | – |
2020 Q1
7 quarters
|
|
16
AnaptysBio
ANAB
$1.36B
| $31.3M | 2.41% |
899,700
| – | – |
2017 Q1
19 quarters
|
|
|
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $30.7M | 2.37% |
1,838,402
| – | – |
2020 Q2
6 quarters
|
|
18
Viridian Therapeutics
VRDN
$2.06B
| $29.8M | 2.29% |
1,505,200
| – | – |
2021 Q3
1 quarter
|
|
|
SRRA
19
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $27.5M | 2.12% |
1,264,861
+460,194
| +57% | +$10.1M |
2015 Q4
24 quarters
|
|
20
Sutro Biopharma
STRO
$183M
| $26.4M | 2.04% |
177,648
+30,782
| +21% | +$5.51M |
2020 Q4
4 quarters
|
|
21
DELISTED
Alpine Immune Sciences Inc
ALPN
| $24.7M | 1.9% |
1,784,913
+13,069
| +0.7% | +$162K |
2017 Q3
17 quarters
|
|
|
22
Silence Therapeutics
SLN
$551M
| $21.2M | 1.63% |
+886,173
| New | +$20.5M |
2021 Q4
0 quarters
|
|
23
Autolus Therapeutics
AUTL
$431M
| $19.4M | 1.5% |
3,746,857
+216,200
| +6% | +$1.3M |
2021 Q2
2 quarters
|
|
|
24
DELISTED
Merus
MRUS
| $17.8M | 1.37% |
+559,179
| New | +$15.8M |
2021 Q4
0 quarters
|
|
25
Replimune Group
REPL
$1.14B
| $17.6M | 1.36% |
650,862
+158,864
| +32% | +$4.75M |
2021 Q3
1 quarter
|
|
Similar funds
ACMV
FRCMI
DB
NAM
AP
ID
CI
DIF
Frazier Management's Q4 2021 Portfolio in Review
As of Q4 2021, Frazier Management held 47 positions worth $1.3B, up 3.9% from $1.25B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Frazier Management deployed $130M of net new capital in Q4 2021, opening 6 new positions and adding to 12 existing holdings. Its largest new stake was Pardes Biosciences, Inc. Common Stock: 2,457,507 shares worth $40.2M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $20.4M trimmed.
- Frazier Management's largest Q4 2021 buy was Pardes Biosciences, Inc. Common Stock: 2,457,507 shares worth $40.2M.
- Frazier Management added most to Syndax Pharmaceuticals in Q4 2021, an estimated $29.3M increase.
- Frazier Management's biggest Q4 2021 reduction was Iovance Biotherapeutics, cutting an estimated $20.4M.
- Frazier Management fully exited Trillium Therapeutics Inc. in Q4 2021, selling an estimated $55M.
- Frazier Management's ten largest holdings make up 56% of its $1.3B portfolio in Q4 2021.
- Frazier Management opened 6 new positions and closed 4 in Q4 2021.
- Frazier Management's portfolio value rose 3.9% quarter-over-quarter to $1.3B.
Based on Frazier Management's 13F filing for Q4 2021, filed 8 Feb 2022.